Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeFRA:N2U0 +9.64%11 Market Cap is €586.04 Mil as of Jul. 18, 2026. GuruFocus rates FRA:N2U0 with a GF Score™ of 11/100. The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Adlai Nortye ranks better than 76.18% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Adlai Nortye's share price for the quarter that ended in Dec. 2025 was €1.46. Adlai Nortye's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 40.00 Mil. Therefore, Adlai Nortye's market cap for the quarter that ended in Dec. 2025 was €58.40 Mil.
Adlai Nortye's quarterly market cap
declined
from Dec. 2024 (€402.21 Mil) to Jun. 2025 (€47.23 Mil) but then
increased
from Jun. 2025 (€47.23 Mil) to Dec. 2025 (€58.40 Mil).
Adlai Nortye's annual market cap
increased
from Dec. 2023 (€273.06 Mil) to Dec. 2024 (€402.21 Mil) but then
declined
from Dec. 2024 (€402.21 Mil) to Dec. 2025 (€58.40 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Adlai Nortye's Enterprise Value for Today is €602.05 Mil.
Adlai Nortye (FRA:N2U0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Adlai Nortye Market Cap Related Terms
Adlai Nortye Market Cap Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:N2U0 vs OMER, PRME, DNA: Market Cap Comparison
For the Biotechnology subindustry, Adlai Nortye's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Market Cap distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Adlai Nortye's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (FRA:N2U0) has a Market Cap of €586.04 Mil as of Jul. 18, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #339 out of 1423 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Adlai Nortye's Market Cap too high?
Adlai Nortye's current Market Cap is €586.04 Mil. Based on the distribution chart, Adlai Nortye ranks #339 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adlai Nortye has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's Market Cap compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #339 out of 1423 companies for Market Cap. This places Adlai Nortye in the top 24% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.78, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median Market Cap is 113.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Market Cap is €586.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (FRA:N2U0) has a current Market Cap of €586.04 Mil. The current Market Cap is €586.04 Mil. Adlai Nortye's overall GF Score™ is 11/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Adlai Nortye (FRA:N2U0), the current Market Cap is €586.04 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
11GF Score
Get the complete analysis for FRA:N2U0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N2U0 has been successfully added to your 
